Amgen and Servier Extend Omecamtiv Mecarbil Collaboration in Chronic Heart Failure


Sept. 1, 2016

Amgen and Servier have announced that their cardiovascular collaboration advances, with the decision of Servier to exercise its option to commercialize omecamtiv mecarbil in chronic heart failure in Europe, as well in as the Commonwealth of Independent States, including Russia. The pharma companies also announced that the omecamtiv mecarbil Phase 3 development program will move forward in collaboration with Cytokinetics.

As per the terms of the agreement, Servier will make a $10 million option exercise payment, as well as future milestone and royalty payments, to Amgen. Servier will also assume a share of the development costs. The decision to advance omecamtiv mecarbil into Phase 3 was based on positive results from COSMIC-HF, a Phase 2 trial evaluating the treatment in patients with chronic heart failure

Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, said: “We are very pleased to strengthen our collaboration with Servier and for the continued advancement of the novel cardiac myosin activator omecamtiv mecarbil. We are working closely with our research collaborators and regulators on the Phase 3 outcomes study for omecamtiv mecarbil and look forward to assessing the potential of this unique therapy to benefit patients with chronic heart failure worldwide.”

“Omecamtiv mecarbil is a very innovative approach to treating chronic heart failure, bringing new hope to patients suffering from this severe condition. We are pleased to collaborate with Amgen in the late stage of its clinical development for omecamtiv mecarbil,” said Emmanuel Canet, M.D., Ph.D., executive vice-president of Research and Development at Servier.

Amgen and Servier Extend Omecamtiv Mecarbil Collaboration in Chronic Heart Failure last edit: 2016-09-13T17:07:19+00:00 da Luca

Leave a Reply

*The views and opinions expressed on IgeaHub belong to the authors only. They do not represent the views or opinions of any company or organization.

Follow Us

Join us

All rights reserved. Terms of use and Privacy Policy

Design by PT Webmaster

%d bloggers like this:
Skip to toolbar